#Rheumatoid #Arthritis Drugs Taken During Pregnancy May Not Be Linked to Large Infection Risk in Children
May 24, 2018 (Investorideas.com Newswire) New research indicates that when pregnant women take certain rheumatoid arthritis (RA) drugs that may cause immunosuppression, their children do not have a marked excess risk of developing serious infections. The Arthritis & Rheumatology findings are potentially encouraging for women with RA who are or wish to become pregnant.
In North America, infections are the leading cause of mortality in children less than 5 years. There are concerns that tumor necrosis factor inhibitors (TNFis), which are used to treat RA and are transported across the placenta, may cause immunosuppression and compromise young children's ability to fight infections; however, there are limited data on the risk of serious infection in children whose mothers used the drugs during pregnancy.
To investigate, Évelyne Vinet MD, PhD, of the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, Quebec, and her colleagues used US claim data from 2011 to 2015 to identify 2,989 offspring of women with rheumatoid arthritis and a randomly selected group of 14,596 control children, matched ≥4:1 for maternal age, year of delivery, and state of residence. The researchers defined TNFi exposure based on at least one filled prescription during pregnancy. Children were followed from birth until 12 months of age, first indication of serious infection, end of commercial insurance eligibility, death, or end of study period (December 30, 2015), whichever came first.
Among offspring of women with RA, 380 (12.7 percent) were exposed to TNFis during pregnancy. The percent of serious infections in those with no TNFi exposure was similar (2.0 percent) to control offspring (1.9 percent), while the percent of serious infections in offspring with TNFi exposure was 3.2 percent. After adjusting for maternal demographics, co-morbidities, pregnancy complications, and medications, however, the investigators were unable to establish an increased risk of serious infections in offspring exposed to TNFis versus both control offspring and offspring of mothers with RA who did not use TNFis.
"Our study provides new evidence to counsel RA women contemplating pregnancy," said Dr. Vinet. "Within the largest cohort of RA offspring exposed to TNFis ever assembled, we did not observe a marked excess risk for serious infections versus unexposed RA offspring and children from the general population. Our data are potentially reassuring, however, we could not exclude a differential risk according to specific TNFi characteristics, with infliximab potentially resulting in a 3-fold increase in the risk of serious infections compared with other TNFis."
Dr. Vinet emphasized that until further studies are conducted to address this issue, it is very important to follow current recommendations when treating women during pregnancy. The European League Against Rheumatism recommends discontinuing infliximab and adalimumab before 20 weeks of gestation and etanercept before 31 to 32 weeks to minimize the risk of infections in offspring, while certolizumab can be continued throughout pregnancy.
The information contained in this release is protected by copyright. Members of the media may sign up for embargoed news or to request a copy of any study please contact:
Dawn Peters (US) +1 781-388-8408
Follow us on Twitter @WileyNews
"Serious infections in rheumatoid arthritis offspring exposed to tumour necrosis factor α inhibitors: cohort study." Évelyne Vinet, Cristiano De Moura, Christian A Pineau, Michal Abrahamowicz, Jeffrey R. Curtis, and Sasha Bernatsky. Arthritis & Rheumatology; Published Online: May 17, 2018 (DOI: 10.1002/art.40536).
URL Upon Publication: http://doi.wiley.com/10.1002/art.40536
Author Contact: Paul Logothetis, Communications Coordinator, McGill University Health Centre at firstname.lastname@example.org or (+1) 514-210-6376.
About the Journal
Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (www.rheumatology.org) is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.
Wiley, a global research and learning company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at www.wiley.com.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.